227 related articles for article (PubMed ID: 24600204)
1. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Daikuhara H; Fukunaga K; Ohshima T
Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
6. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
[TBL] [Abstract][Full Text] [Related]
8. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Minatoguchi S; Aoyama T; Kawai N; Iwasa M; Oda M; Kida K; Kojima S; Goto N; Goto M; Sugishita F; Takai K; Tanaka R; Hiei K; Minagawa T; Yamamoto N; Watanabe I; Yasue T; Kobayashi H
Blood Press; 2013 Sep; 22 Suppl 1():29-37. PubMed ID: 23330658
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
[TBL] [Abstract][Full Text] [Related]
10. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
Kinoshita S; Ryuzaki M; Sone M; Nishida E; Nakamoto H;
Clin Exp Hypertens; 2014; 36(7):508-16. PubMed ID: 24433108
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements.
Wang JG; Sun NL; Ke YN; Zhang BH; Ikegami N; Zhu JR
Clin Drug Investig; 2012 Nov; 32(11):729-34. PubMed ID: 23018282
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.
Sasaki T; Noda Y; Yasuoka Y; Irino H; Abe H; Adachi H; Hattori S; Kitada H; Morisawa D; Miyatake K
Hypertens Res; 2008 May; 31(5):921-9. PubMed ID: 18712048
[TBL] [Abstract][Full Text] [Related]
14. Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST study at 16 weeks.
Kario K; Saito I; Kushiro T; Teramukai S; Ishikawa Y; Hiramatsu K; Kobayashi F; Shimada K
J Hum Hypertens; 2013 Dec; 27(12):721-8. PubMed ID: 23863805
[TBL] [Abstract][Full Text] [Related]
15. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Vogt L; Navis G; Köster J; Manolis AJ; Reid JL; de Zeeuw D;
J Hypertens; 2005 Nov; 23(11):2055-61. PubMed ID: 16208149
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
Ushigome E; Matsumoto S; Oyabu C; Ushigome H; Yokota I; Hasegawa G; Nakamura N; Tanaka M; Yamazaki M; Fukui M
J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
